Stoke Therapeutics, an innovative biopharmaceutical company, is tackling severe genetic diseases using cutting-edge technology. Employing its targeted augmentation of nuclear gene output, Stoke has created a range of antisense oligonucleotides aimed at restoring protein levels by selectively targeting the underlying causes of these diseases. Currently, its flagship drug, STK-002, is in the preclinical stage for treating autosomal dominant optic atrophy. Stoke's pipeline includes multiple drugs such as STK-001, which is in phase I/II clinical trials to treat Dravet syndrome. Additionally, Stoke is developing programs focused on haploinsufficiency diseases and conditions of the nervous system and eyes. Stoke is also expanding through collaborations like its license and partnership with Acadia Pharmaceuticals Inc. to discover, develop and commercialize novel RNA-based medicines that treat severe and rare genetic neurodevelopmental diseases of the central nervous system. Based in Bedford, Massachusetts, Stoke Therapeutics Inc. previously operated as ASOthera Pharmaceuticals, Inc. before changing its name in May 2016. Despite being a relatively new company, established in 2014, Stoke Therapeutics is poised to make a substantial impact on the pharmaceutical industry.
Stoke Therapeutics's ticker is STOK
The company's shares trade on the NASDAQ stock exchange
They are based in Bedford, Massachusetts
There are 51-200 employees working at Stoke Therapeutics
It is stoketherapeutics.com
Stoke Therapeutics is in the Healthcare sector
Stoke Therapeutics is in the Biotechnology industry
The following five companies are Stoke Therapeutics's industry peers: